[BMRN] BioMarin Pharmaceutical Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 85.66 Change: 2.12 (2.54%)
Ext. hours: Change: 0 (0%)

chart BMRN

Refresh chart

Strongest Trends Summary For BMRN

BMRN is in the medium-term down -13% below S&P in 5 months. In the long-term up 90% above S&P in 24 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: BioMarin Pharmaceutical Inc. develops and commercializes biopharmaceuticals for serious diseases and medical conditions in the United States, Europe, Latin America, and internationally. Its commercial products include Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase enzyme for the treatment of mucopolysaccharidosis VI; Kuvan, a proprietary synthetic oral form of 6R-BH4 used to treat patients with phenylketonuria (PKU), a metabolic disease; Aldurazyme used for the treatment of mucopolysaccharidosis I, a genetic disease; Firdapse used to treat Lambert Eaton Myasthenic Syndrome, an autoimmune disease; and Vimizim, an enzyme replacement therapy to treat MPS IVA, a lysosomal storage disorder. The company also develops PEG-PAL, an enzyme substitution therapy that is under Phase III clinical trial to treat PKU; BMN-701, an enzyme replacement therapy, which is under Phase I/II clinical trial for Pompe disease, a glycogen storage disorder; BMN-673, a poly ADP-ribose polymerase inhibitor that is in Ph

Fundamental Ratios
Shares Outstanding EPS-1.02 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 5.98% Sales Growth - Q/Q-11.95% P/E-86.75
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-4.46% ROE-6.74% ROI-5.17%
Current Ratio4.98 Quick Ratio4.25 Long Term Debt/Equity0.54 Debt Ratio0.13
Gross Margin82.59% Operating Margin-16.48% Net Profit Margin-20.35% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities914.79 M Cash From Investing Activities-750.87 M Cash From Operating Activities-137.81 M Gross Profit170.45 M
Net Profit-67.5 M Operating Profit-66.02 M Total Assets3.66 B Total Current Assets1.52 B
Total Current Liabilities305.51 M Total Debt655.49 M Total Liabilities1.23 B Total Revenue203.26 M
Technical Data
High 52 week106.07 Low 52 week78.04 Last close88.71 Last change-1.07%
RSI57.48 Average true range2.65 Beta1.08 Volume685.95 K
Simple moving average 20 days5.02% Simple moving average 50 days0.72% Simple moving average 200 days-5.5%
Performance Data
Performance Week7.62% Performance Month7.72% Performance Quart-5.62% Performance Half-5.14%
Performance Year-0.9% Performance Year-to-date4.18% Volatility daily2.04% Volatility weekly4.56%
Volatility monthly9.34% Volatility yearly32.35% Relative Volume211.9% Average Volume1.17 M
New High New Low


2019-06-17 13:52:12 | Nasdaq Outperforms, Helped By Software, Biotech; Bitcoin Trading Heats Up

2019-06-13 21:08:21 | Chicago biotech sues Third Rock, bluebird bio CEO over gene therapy license

2019-06-12 07:30:00 | 9 major Bay Area tech employers pay a typical worker more than $200K per year

2019-06-11 16:40:47 | 'Something worth doing': How a biotech entrepreneur grew a 700-person company and is conquering rare diseases

2019-06-11 10:24:02 | Here is What Hedge Funds Think About BioMarin Pharmaceutical Inc. BMRN

2019-06-10 09:03:39 | Should BioMarin Pharmaceutical NASDAQ:BMRN Be Disappointed With Their 32% Profit?

2019-06-10 08:04:04 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-06-09 12:09:00 | 3 Top Growth Stocks to Buy in June

2019-06-06 10:33:02 | BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady

2019-06-05 08:30:00 | BioMarin to Participate in Goldman Sachs 40th Annual Global Healthcare Conference on Tuesday, June 11 in Rancho Palos Verdes, CA

2019-06-04 08:30:00 | BioMarin Announces Approval of Vimizim® elosulfase alfa in China for Treatment of Morquio A Syndrome

2019-06-02 11:08:33 | 5 Best-Rated Stocks To Buy Amid Selloff

2019-05-31 10:39:00 | Is the $2.1 Million Price Tag for Novartis' Zolgensma Ridiculous?

2019-05-29 10:52:02 | BioMarin Announces Data on Hemophilia Candidate, Shares Fall

2019-05-29 10:22:02 | Biotech Stock Roundup: AMGN's Nuevolution Buyout, CELG, INCY Drugs' Label Expansion

2019-05-28 19:46:00 | How BioMarin May Revolutionize the Hemophilia Treatment Market

2019-05-28 17:35:39 | A hemophilia patient hero at zero, BioMarin to seek FDA OK for gene therapy. But will the effect last?

2019-05-28 17:00:07 | What Happened in the Stock Market Today

2019-05-28 16:45:00 | BioMarin’s 2019 Stock Gains Erased After Release of Gene Therapy Data

2019-05-28 16:22:38 | This Biotech Had Positive Data In Gene Therapy — But It Wasn't Enough

2019-05-28 10:21:27 | BioMarin's hemophilia gene therapy data shows promise

2019-05-28 07:11:31 | BioMarin says hemophilia gene therapy meets certain criteria in late-stage trial

2019-05-28 06:55:00 | BioMarin Announces that Phase 3 Cohort of Valoctocogene Roxaparvovec, Gene Therapy Study in Severe Hemophilia A Met Pre-Specified Criteria for Regulatory Submissions in the U.S. and Europe

2019-05-28 06:50:00 | BioMarin Provides 3 Years of Clinical Data from Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

2019-05-27 16:00:00 | BioMarin to Host Conference Call Tuesday, May 28, 2019 to Provide a Valoctocogene Roxaparvovec Phase 2 and Phase 3 Update

2019-05-26 09:00:00 | 3 Big Biotech Stocks That Warren Buffett Might Like

2019-05-22 10:02:00 | BioMarin Stock Is a Buy, With or Without Hemophilia Treatment, J.P. Morgan Says

2019-05-16 08:42:12 | BioMarin BMRN in Focus: Stock Moves 7.5% Higher

2019-05-16 08:30:00 | BioMarin to Participate in 2019 RBC Capital Markets Global Healthcare Conference on May 21 in New York City

2019-05-14 11:30:00 | 2 Stocks You Definitely Should Consider Shorting This Week

2019-05-10 08:55:34 | Read This Before Buying BioMarin Pharmaceutical Inc. NASDAQ:BMRN Shares

2019-05-09 13:11:25 | BioMarin Bulls Are Counting on Gene Therapy to Reignite the Stock

2019-05-09 11:05:03 | Sarepta SRPT Q1 Earnings Top Estimates, Exondys 51 Sales Up

2019-05-08 08:31:00 | Here's How I'm Playing an Increasingly Volatile Market With These 2 Biotechs

2019-05-08 08:30:00 | BioMarin to Participate in Bank of America Merrill Lynch Health Care Conference on May 15 in Las Vegas

2019-05-07 08:04:02 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-05-07 07:30:00 | Netflix and Google now pay a typical employee more than $200K per year. Here's how that compares to Facebook, Intel, Twitter and other big Bay Area tech employers.

2019-05-06 10:12:00 | European Commission Approves Palynziq® pegvaliase injection for Treatment of Phenylketonuria PKU in Patients Aged 16 Years or Older

2019-05-02 14:18:14 | 5 Biotech Stocks With Near-Term Catalysts Ahead

2019-05-01 14:29:00 | BioMarin Isn't a "Gene Therapy Company"

2019-04-30 08:04:13 | See what the IHS Markit Score report has to say about Biomarin Pharmaceutical Inc.

2019-04-26 20:44:19 | Edited Transcript of BMRN earnings conference call or presentation 25-Apr-19 8:30pm GMT

2019-04-26 14:04:06 | BioMarin BMRN Shares Down Despite Q1 Earnings & Sales Beat

2019-04-26 08:02:57 | The Daily Biotech Pulse: Mixed Results For Merck's Keytruda In Stomach Cancer; Roche's Spark-Buy Delayed, Teva Recalls Hypertension Drug

2019-04-26 03:31:38 | Biomarin Pharmaceutical Inc BMRN Q1 2019 Earnings Call Transcript

2019-04-25 16:52:31 | BioMarin: 1Q Earnings Snapshot

2019-04-25 16:05:00 | BioMarin Announces First Quarter 2019 Financial Results

2019-04-25 14:30:00 | BioMarin Pharmaceutical Inc. to Host Earnings Call

2019-04-25 07:58:40 | The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings

2019-04-24 09:15:01 | Solid Earnings Boost S&P, NASDAQ to New Closing Highs